Net Income (Loss) Attributable to Parent in USD of Aptevo Therapeutics Inc. from Q1 2015 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Aptevo Therapeutics Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from Q1 2015 to Q3 2025.
  • Aptevo Therapeutics Inc. Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$7.55M, a 48% decline year-over-year.
  • Aptevo Therapeutics Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$26.5M, a 11.6% decline year-over-year.
  • Aptevo Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$24.1M, a 38.6% decline from 2023.
  • Aptevo Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$17.4M, a 317% decline from 2022.
  • Aptevo Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2022 was $8.03M.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Aptevo Therapeutics Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$26.5M -$7.55M -$2.45M -48% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025
Q2 2025 -$24M -$6.2M -$321K -5.46% 01 Apr 2025 30 Jun 2025 10-Q 06 Nov 2025
Q1 2025 -$23.7M -$6.41M +$426K +6.23% 01 Jan 2025 31 Mar 2025 10-Q 06 Nov 2025
Q4 2024 -$24.1M -$6.31M -$410K -6.95% 01 Oct 2024 31 Dec 2024 10-K 14 Feb 2025
Q3 2024 -$23.7M -$5.1M +$1.23M +19.5% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025
Q2 2024 -$25M -$5.88M +$2.07M +26% 01 Apr 2024 30 Jun 2024 10-Q 06 Nov 2025
Q1 2024 -$27M -$6.83M -$9.61M -346% 01 Jan 2024 31 Mar 2024 10-Q 06 Nov 2025
Q4 2023 -$17.4M -$5.9M -$1.26M -27.1% 01 Oct 2023 31 Dec 2023 10-K 14 Feb 2025
Q3 2023 -$16.2M -$6.33M +$1.31M +17.1% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024
Q2 2023 -$17.5M -$7.95M -$36M -128% 01 Apr 2023 30 Jun 2023 10-Q 07 Nov 2024
Q1 2023 $18.5M $2.77M +$10.5M 01 Jan 2023 31 Mar 2023 10-Q 07 Nov 2024
Q4 2022 $8.03M -$4.64M +$1.63M +26% 01 Oct 2022 31 Dec 2022 10-K 05 Mar 2024
Q3 2022 $6.4M -$7.64M -$647K -9.25% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 $7.04M $28M +$35.9M 01 Apr 2022 30 Jun 2022 10-Q 14 Nov 2023
Q1 2022 -$28.9M -$7.7M -$441K -6.08% 01 Jan 2022 31 Mar 2022 10-Q 14 Nov 2023
Q4 2021 -$28.5M -$6.27M +$781K +11.1% 01 Oct 2021 31 Dec 2021 10-K 30 Mar 2023
Q3 2021 -$29.2M -$7M -$206K -3.03% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 -$29M -$7.93M -$1.13M -16.6% 01 Apr 2021 30 Jun 2021 10-Q 10 Nov 2022
Q1 2021 -$27.9M -$7.26M -$10.2M -350% 01 Jan 2021 31 Mar 2021 10-Q 10 Nov 2022
Q4 2020 -$17.8M -$7.05M +$1.12M +13.7% 01 Oct 2020 31 Dec 2020 10-K 24 Mar 2022
Q3 2020 -$18.9M -$6.79M +$133K +1.92% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 -$19M -$6.8M +$6.53M +49% 01 Apr 2020 30 Jun 2020 10-Q 12 Nov 2021
Q1 2020 -$25.5M $2.9M +$14.9M 01 Jan 2020 31 Mar 2020 10-Q 12 Nov 2021
Q4 2019 -$40.4M -$8.17M +$5.96M +42.1% 01 Oct 2019 31 Dec 2019 10-K 31 Mar 2021
Q3 2019 -$46.4M -$6.92M +$5.64M +44.9% 01 Jul 2019 30 Sep 2019 10-Q 10 Nov 2020
Q2 2019 -$52M -$13.3M -$188K -1.43% 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020
Q1 2019 -$51.9M -$12M +$1.84M +13.3% 01 Jan 2019 31 Mar 2019 10-Q 13 May 2020
Q4 2018 -$53.7M -$14.1M -$4.37M -44.8% 01 Oct 2018 31 Dec 2018 10-K 25 Mar 2020
Q3 2018 -$49.3M -$12.6M -$50.4M -133% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019
Q2 2018 $1.11M -$13.1M -$1.96M -17.5% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019
Q1 2018 $3.06M -$13.9M -$3.91M -39.3% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019
Q4 2017 $6.97M -$9.76M +$5.19M +34.7% 01 Oct 2017 31 Dec 2017 10-K 18 Mar 2019
Q3 2017 $1.79M $37.9M +$110M 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018
Q2 2017 -$108M -$11.2M +$1.65M +12.8% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018
Q1 2017 -$109M -$9.95M +$2.94M +22.8% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018
Q4 2016 -$112M -$14.9M +$2.95M +16.5% 01 Oct 2016 31 Dec 2016 10-K 31 Mar 2017
Q3 2016 -$115M -$71.7M -$59.1M -466% 01 Jul 2016 30 Sep 2016 10-Q 13 Nov 2017
Q2 2016 -$56.3M -$12.8M +$4.88M +27.5% 01 Apr 2016 30 Jun 2016 10-Q 10 Aug 2017
Q1 2016 -$61.2M -$12.9M -$1.87M -16.9% 01 Jan 2016 31 Mar 2016 10-Q 12 May 2017
Q4 2015 -$59.3M -$17.9M 01 Oct 2015 31 Dec 2015 10-K 31 Mar 2017
Q3 2015 -$12.7M 01 Jul 2015 30 Sep 2015 10-K 31 Mar 2017
Q2 2015 -$17.7M 01 Apr 2015 30 Jun 2015 10-K 31 Mar 2017
Q1 2015 -$11M 01 Jan 2015 31 Mar 2015 10-K 31 Mar 2017

Aptevo Therapeutics Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$24.1M -$6.72M -38.6% 01 Jan 2024 31 Dec 2024 10-K 14 Feb 2025
2023 -$17.4M -$25.4M -317% 01 Jan 2023 31 Dec 2023 10-K 14 Feb 2025
2022 $8.03M +$36.5M 01 Jan 2022 31 Dec 2022 10-K 05 Mar 2024
2021 -$28.5M -$10.7M -60.3% 01 Jan 2021 31 Dec 2021 10-K 30 Mar 2023
2020 -$17.8M +$22.7M +56.1% 01 Jan 2020 31 Dec 2020 10-K 24 Mar 2022
2019 -$40.4M +$13.2M +24.7% 01 Jan 2019 31 Dec 2019 10-K 31 Mar 2021
2018 -$53.7M -$60.7M -870% 01 Jan 2018 31 Dec 2018 10-K 25 Mar 2020
2017 $6.97M +$119M 01 Jan 2017 31 Dec 2017 10-K 18 Mar 2019
2016 -$112M -$53.1M -89.5% 01 Jan 2016 31 Dec 2016 10-K 13 Mar 2018
2015 -$59.3M 01 Jan 2015 31 Dec 2015 10-K 31 Mar 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.